Surgery Partners (NASDAQ:SGRY) Price Target Cut to $20.00 by Analysts at TD Cowen

Surgery Partners (NASDAQ:SGRY) had its price objective reduced by TD Cowen from $28.00 to $20.00 in a research report released on Thursday morning,Benzinga reports. TD Cowen currently has a buy rating on the stock.

Other analysts also recently issued reports about the stock. JPMorgan Chase & Co. lowered their price target on shares of Surgery Partners from $27.00 to $20.00 and set a “neutral” rating on the stock in a report on Monday, November 24th. Cantor Fitzgerald reissued an “overweight” rating on shares of Surgery Partners in a research note on Wednesday. Royal Bank Of Canada cut their price target on Surgery Partners from $31.00 to $20.00 and set an “outperform” rating for the company in a research note on Wednesday. UBS Group reduced their price target on Surgery Partners from $29.00 to $21.00 and set a “buy” rating for the company in a report on Thursday. Finally, Jefferies Financial Group reiterated a “buy” rating on shares of Surgery Partners in a research report on Wednesday. Nine investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $24.45.

Surgery Partners Stock Up 0.2%

Surgery Partners stock opened at $14.11 on Thursday. The business’s 50-day moving average price is $15.25 and its 200 day moving average price is $18.21. The company has a quick ratio of 1.72, a current ratio of 1.87 and a debt-to-equity ratio of 1.15. The firm has a market cap of $1.83 billion, a price-to-earnings ratio of -22.76 and a beta of 1.95. Surgery Partners has a 52 week low of $12.25 and a 52 week high of $24.64.

Surgery Partners (NASDAQ:SGRY) last released its quarterly earnings data on Monday, March 2nd. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.31 by ($0.19). The company had revenue of $885.00 million during the quarter, compared to analysts’ expectations of $866.54 million. Surgery Partners had a positive return on equity of 1.28% and a negative net margin of 2.35%.The company’s revenue for the quarter was up 2.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.44 EPS. As a group, sell-side analysts anticipate that Surgery Partners will post 0.67 earnings per share for the current year.

Surgery Partners announced that its board has approved a stock buyback program on Thursday, February 26th that permits the company to buyback $200.00 million in shares. This buyback authorization permits the company to repurchase up to 9.7% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s management believes its shares are undervalued.

Institutional Trading of Surgery Partners

Large investors have recently made changes to their positions in the company. Alpine Global Management LLC acquired a new position in Surgery Partners in the 4th quarter valued at $175,000. Empowered Funds LLC boosted its stake in Surgery Partners by 1,340.9% during the 4th quarter. Empowered Funds LLC now owns 161,419 shares of the company’s stock worth $2,494,000 after purchasing an additional 150,216 shares during the last quarter. One68 Global Capital LLC purchased a new stake in shares of Surgery Partners during the fourth quarter worth $371,000. Man Group plc acquired a new stake in shares of Surgery Partners in the fourth quarter valued at about $5,080,000. Finally, Inspire Investing LLC raised its position in shares of Surgery Partners by 45.4% in the fourth quarter. Inspire Investing LLC now owns 30,073 shares of the company’s stock valued at $465,000 after buying an additional 9,384 shares during the last quarter.

Key Headlines Impacting Surgery Partners

Here are the key news stories impacting Surgery Partners this week:

• Positive Sentiment: Company expansion and strategic deal — Surgery Partners completed the acquisition of Preferred Vascular Group (an ASC operator focused on dialysis-access procedures), expanding its ASC footprint and specialized services. ZIEGLER ADVISES PREFERRED VASCULAR GROUP ON ITS ACQUISITION BY SURGERY PARTNERS
• Positive Sentiment: Shareholder-friendly capital allocation — the board authorized a $200 million buyback (up to ~9.7% of shares), signaling management believes shares are undervalued and supporting EPS/ownership over time. Stock Buybacks
• Neutral Sentiment: Analysts still constructive but revising models — UBS, TD Cowen and Mizuho maintained buy/outperform ratings while cutting price targets (UBS to $21, TD Cowen to $20, Mizuho to $17), reflecting lowered near‑term expectations but continued confidence in recovery potential. Analyst Price Target Coverage TD Cowen PT Cut
• Neutral Sentiment: Earnings were mixed — Q4 showed revenue growth but margin pressures and an EPS miss, which explains both cautious analyst revisions and the short‑term stock weakness. Q4 2025 Earnings Call Highlights
• Negative Sentiment: Price targets and downside pressure — Barclays cut its target to $14 (roughly at the current level), adding downward pressure on sentiment. Barclays Lowers Price Target
• Negative Sentiment: Share price weakness and 52‑week low headlines — multiple outlets report SGRY hit a new 52‑week low after the disappointing earnings print, which can amplify selling and volatility. Sets New 52-Week Low MSN Coverage
• Negative Sentiment: Potential legal overhang — a law firm announced an investigation into possible claims against executives, which can elevate regulatory/legal risk and hurt sentiment until resolved. Johnson Fistel Investigation Notice

Surgery Partners Company Profile

Surgery Partners, Inc operates as a healthcare services provider specializing in the management and ownership of ambulatory surgery centers, surgical hospitals and multispecialty rehabilitation hospitals across the United States. Through its network of facilities, the company coordinates and delivers a broad range of outpatient surgical procedures in specialties such as orthopedics, ophthalmology, otolaryngology, gastroenterology, pain management and general surgery. Its integrated platform offers ancillary services including on-site imaging, laboratory testing, infusion therapy and physical, occupational and speech rehabilitation.

Since its establishment in 2010 and subsequent public listing in 2015, Surgery Partners has focused on strategic partnerships with physicians and health systems to expand access to cost-effective outpatient care.